ME-344-001: Dose Escalation Study of the Safety and Pharmacokinetics of ME-344 Single Agent for Refractory Solid Tumors

Sponsor

MEI Pharma, Inc. (Industry)

Overall Status

Completed

CT.gov ID

NCT01544322

Collaborator

SCRI Development Innovations, LLC (Other)

Enrollment

Locations

Duration (Months)

Patients Per Site

0.3

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The purpose of this study is to determine the tolerability of ME-344, find the maximum tolerated dose, and the safety profile in patients with refractory solid tumors.

Condition or Disease	Intervention/Treatment	Phase
Solid Tumors	Drug: ME-344	Phase 1

Study Design

Study Type:

Interventional

Anticipated Enrollment :

24 participants

Allocation:

N/A

Intervention Model:

Single Group Assignment

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

Phase 1 Open Label Dose Escalation Study of the Safety and Pharmacokinetics of ME-344 as a Single Agent in Patients With Refractory Solid Tumors

Study Start Date :

May 1, 2012

Actual Primary Completion Date :

Aug 1, 2014

Actual Study Completion Date :

Aug 1, 2014

Outcome Measures

Primary Outcome Measures

Dose limiting toxicity [One Cycle of 28 days]
Patients will be administered ME-344 IV infusions weekly for 3 weeks during the first 28 days cycle for dose limiting toxicity. Patients will be assessed by physical exam, vital signs, hematology and clinical chemistry, urinalysis, ECG, echocardiogram and pharmacokinetic sampling.

Secondary Outcome Measures

Response Rate [baseline and a minimum of every 12 weeks]
Radiologic assessments will be performed at baseline and a minimum of every 12 weeks. Patients may continue weekly dosing if there is clinical beneficial determined by the Investigator.

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Provision of informed consent
Male or female ≥ 18 years of age
Histologic or cytologic confirmed locally advanced or metastatic cancer that has no standard therapeutic alternatives.
ECOG Performance status 0-1 (Appendix A)
A minimum life expectancy of 12 weeks
Adequate bone marrow, hepatic and renal function as evidenced by:
Absolute neutrophil count (ANC) > 1.5 x 109/L
Platelet count > 100 x 109/L
Hemoglobin > 9.0 g/dL
Serum bilirubin < 1.5 x ULN
AST/ALT (SGOT/SGPT) < 2.5 x ULN for the reference laboratory or < 5 x ULN in the presence of liver metastases
Serum creatinine < 1.5 x ULN
Adequate cardiac function as evidenced by:
CK-MB within normal levels at baseline
Troponin T within normal levels at baseline
The average QTc from triplicate screening ECGs (every 5 minutes over a total of 15 minutes) must be < 470 msec to be eligible for the study. (If a patient has an average QTc interval >470 msec at screening, the screening ECG may be repeated twice (at least 24 hours apart).
LV Ejection Fraction > lower limit of institutional normal level
All potentially fertile patients will agree to use an effective form of contraception during the study and for 30 days following the last dose of ME-344 (an effective form of contraception is defined as an oral contraceptive or a double barrier method).
At least 4 weeks must have elapsed prior to Day 1 Cycle 1 since prior chemotherapy (6 weeks for nitrosourea or mitomycin C), investigational drug or biologic therapy and any toxicity associated with these treatments has recovered to ≤ NCI-CTCAE Grade 1.
At least 21 days must have elapsed prior to Day 1 Cycle 1, radiotherapy, immunotherapy or following major surgery and any surgical incision should be completely healed. At least 14 days must have elapsed prior to Day 1 Cycle 1 for "limited palliative radiotherapy", defined as a course of therapy encompassing <25% total bone marrow volume and not exceeding 30 Gy.

Exclusion Criteria:

Patients who are pregnant or breastfeeding
Tumor involvement of the Central Nervous System (CNS):
Patients with treated and stable CNS metastases may be eligible to participate after discussion and approval from the Medical Monitor
Uncontrolled infection or systemic disease.
Clinically significant cardiac disease not well controlled with medication (e.g., congestive heart failure, symptomatic coronary artery disease e.g. angina, and cardiac arrhythmias) or myocardial infarction within the last 12 months.
Any major surgery, radiotherapy, or immunotherapy within the last 21 days. Limited palliative radiation, defined as encompassing <25% of total bone marrow volume and not exceeding a total dose of 30 Gy, within the last 14 days.
Chemotherapy regimens with delayed toxicity within the last 4 weeks (or within 6 weeks for prior nitrosourea or mitomycin C). Chemotherapy regimens given continuously or on a weekly basis with limited potential or delayed toxicity within the last 2 weeks.
No concurrent systemic chemotherapy or biologic therapy is allowed.
Known hypersensitivity to any components of ME-344 study drug product.
Known human immunodeficiency virus (HIV) or Hepatitis B or C (active, previously treated or both).
History of solid organ transplantation.
Psychiatric disorder or social or geographic situation that would preclude study participation.

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Florida Cancer Specialists	Sarasota	Florida	United States	34232
2	University of Oklahoma	Oklahoma City	Oklahoma	United States	73104
3	Tennessee Oncology, PLLC	Nashville	Tennessee	United States	73104